Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors

被引：10
作者：
Cheng, Yue-Juan [1 ]
Meng, Chang-Ting [1 ]
Ying, Hong-Yan [1 ]
Zhou, Jian-Feng [1 ]
Yan, Xiao-Yan [2 ]
Gao, Xin [3 ]
Zhou, Na [1 ]
Bai, Chun-Mei [1 ]
机构：
[1] Peking Union Med Coll Hosp, Dept Med Oncol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[2] Peking Univ, Clin Res Inst, Dept Biostat, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
来源：
MEDICINE | 2018年 / 97卷 / 45期
关键词：
dacarbazine; endostar; 5-fluorouracil; pancreatic neuroendocrine tumors; survival; temozolomide; PHASE-II TRIAL; TEMOZOLOMIDE; EFFICACY; STREPTOZOCIN; 5-FLUOROURACIL; FLUOROURACIL; MULTICENTER; BEVACIZUMAB; DACARBAZINE; SAFETY;
D O I：
10.1097/MD.0000000000012750
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs). Phase II study of 14 patients with locally advanced or metastatic well-differentiated pNETs treated between April 2013 and September 2016. Patients received temozolomide or dacarbazine plus 5-FU, and Endostar. The primary outcome was the radiographic response rate. All 14 patients had nonfunctional pNETs. Six patients received temozolomide and 8 received dacarbazine + 5-FU, combined with Endostar. Thirteen patients were assessable for treatment response: 1(7%) with complete response, 5 (39%) with partial response, 5 (39%) with stable disease, and 2 (15%) with progression. The median progression-free survival was 12 months. The most common grade 1/2 toxicities were neutropenia (43%) and leucopenia (21%). Endostar combined with temozolomide or dacarbazine + 5-FU was effective in the treatment of advanced pNETs. The combinations were well tolerated.
引用
收藏
页数：5
相关论文
共 50 条
[31]   Efficacy of Capecitabine and Temozolomide Combination in Well-Differentiated Neuroendocrine Tumors Jordan Experience [J].
Abbasi, Salah ;
Kashashna, Amneh ;
Albaba, Hamzeh .
PANCREAS, 2014, 43 (08) :1303-1305
[32]   An unexpected effect of chronic treatment with Temozolomide in patients with metastatic, well-differentiated neuroendocrine tumors [J].
Laffi, A. ;
Nicosia, L. ;
Spada, F. ;
Rubino, M. ;
Fazio, N. .
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :138-138
[33]   Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis [J].
Pozzari, Marta ;
Maisonneuve, Patrick ;
Spada, Francesca ;
Berruti, Alfredo ;
Amoroso, Vito ;
Cella, Chiara Alessandra ;
Laffi, Alice ;
Pellicori, Stefania ;
Bertani, Emilio ;
Fazio, Nicola .
CANCER TREATMENT REVIEWS, 2018, 71 :39-46
[34]   Comparison of Methods for Proliferative Index Analysis for Grading Pancreatic Well-Differentiated Neuroendocrine Tumors [J].
Goodell, Pamela P. ;
Krasinskas, Alyssa M. ;
Davison, Jon M. ;
Hartman, Douglas J. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 137 (04) :576-582
[35]   Mesenteric Lymphadenectomy in Well-Differentiated Appendiceal Neuroendocrine Tumors [J].
Raoof, Mustafa ;
Dumitra, Sinziana ;
O'Leary, Michael P. ;
Singh, Gagandeep ;
Fong, Yuman ;
Lee, Byrne .
DISEASES OF THE COLON & RECTUM, 2017, 60 (07) :674-681
[36]   Risk Stratification of Well-Differentiated Rectal Neuroendocrine Tumors [J].
Zhang, Y. ;
Chen, L. ;
Zhang, Y. ;
Guan, X. ;
Pan, Y. ;
Chen, M. H. ;
Chen, J. .
NEUROENDOCRINOLOGY, 2020, 110 :116-116
[37]   Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor [J].
Nanno, Yoshihide ;
Matsumoto, Ippei ;
Zen, Yoh ;
Otani, Kyoko ;
Uemura, Jun ;
Toyama, Hirochika ;
Asari, Sadaki ;
Goto, Tadahiro ;
Ajiki, Tetsuo ;
Okano, Keiichi ;
Suzuki, Yasuyuki ;
Takeyama, Yoshifumi ;
Fukumoto, Takumi ;
Ku, Yonson .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (04) :1127-1133
[38]   Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well-differentiated pancreatic neuroendocrine tumors [J].
de Mestier, L. ;
Cohen, D. ;
de Rycke, O. ;
Planchon, Masliah J. ;
Fleischmann, Z. ;
Sivakumar, S. ;
Sokol, E. ;
Hent, O. ;
Ruszniewski, P. ;
Couvelard, A. ;
Bieche, I ;
Cros, J. .
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 :233-233
[39]   Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors [J].
Pulvirenti, Alessandra ;
Pea, Antonio ;
Chang, David K. ;
Jamieson, Nigel B. .
FRONTIERS IN MEDICINE, 2020, 7
[40]   In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors [J].
Lyons, John M., III ;
Abergel, Jeffrey ;
Thomson, Jessica L. ;
Anthony, Cathy T. ;
Wang, Yi-Zarn ;
Anthony, Lowell B. ;
Boudreaux, J. Philip ;
Strauchen, James ;
Idrees, Muhammad ;
Warner, Richard R. P. ;
Woltering, Eugene A. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (03) :649-655
12345